Extracellular Vesicles: A New Star for Gene Drug Delivery
Man Sun,Huan Zhang,Jiayi Liu,Jiayi Chen,Yaxin Cui,Simiao Wang,Xiangyu Zhang,Zhaogang Yang
DOI: https://doi.org/10.2147/ijn.s446224
IF: 7.033
2024-03-07
International Journal of Nanomedicine
Abstract:Man Sun, 1 Huan Zhang, 1 Jiayi Liu, 1 Jiayi Chen, 1 Yaxin Cui, 1 Simiao Wang, 1 Xiangyu Zhang, 2 Zhaogang Yang 1 1 School of Life Sciences, Jilin University, Changchun, 130012, People's Republic of China; 2 Department of General Surgery, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, 310020, People's Republic of China Correspondence: Xiangyu Zhang; Zhaogang Yang, Tel/Fax +86-431-85155320, Email ; Recently, gene therapy has become a subject of considerable research and has been widely evaluated in various disease models. Though it is considered as a stand-alone agent for COVID-19 vaccination, gene therapy is still suffering from the following drawbacks during its translation from the bench to the bedside: the high sensitivity of exogenous nucleic acids to enzymatic degradation; the severe side effects induced either by exogenous nucleic acids or components in the formulation; and the difficulty to cross the barriers before reaching the therapeutic target. Therefore, for the successful application of gene therapy, a safe and reliable transport vector is urgently needed. Extracellular vesicles (EVs) are the ideal candidate for the delivery of gene drugs owing to their low immunogenicity, good biocompatibility and low toxicity. To better understand the properties of EVs and their advantages as gene drug delivery vehicles, this review covers from the origin of EVs to the methods of EVs generation, as well as the common methods of isolation and purification in research, with their pros and cons discussed. Meanwhile, the engineering of EVs for gene drugs is also highlighted. In addition, this paper also presents the progress in the EVs-mediated delivery of microRNAs, small interfering RNAs, messenger RNAs, plasmids, and antisense oligonucleotides. We believe this review will provide a theoretical basis for the development of gene drugs. Keywords: extracellular vesicles, gene therapy, drug delivery system, gene drugs In recent years, gene therapy has been widely evaluated to treat or ameliorate diseases. It can be generally defined as the transfer of gene materials to treat a disease or improve a patient's clinical condition. 1 Compared with traditional therapy, gene therapy, including gene replacement therapy, gene repair therapy and gene inhibition therapy, presents high specificity and low toxicity, and it brings a revolutionary treatment option for most genetic-related diseases. 2 Currently, many gene drugs, mainly including microRNAs (miRNAs), small interfering RNAs (siRNAs), messenger RNAs (mRNAs), circular RNAs (circRNAs), plasmid DNAs (pDNAs), antisense oligonucleotides (ASOs), CRISPR/Cas9 and DNA aptamers, have been evaluated for gene therapy. 3–7 Moreover, some gene drugs, including fomivirsen, mipomersen, defibrotide, and patisiran, have been approved by the US Food and Drug Administration (FDA) for clinical use. 8 Although these gene drugs have shown potential therapeutic effects, some limitations still exist before their translation from the bench to the bedside. For example, gene drugs can be easily degraded in vivo and they also lack active targeting, resulting in low therapeutic efficiency but high cytotoxicity for health organs. 9–11 Meanwhile, in order to improve their therapeutic efficiency, most gene drugs require the co-treatment with steroids and antihistamines which may results in the undesired side effects. Therefore, a safe and efficient delivery of gene drugs is critical for the successful gene therapy. 12,13 To address these problems, many researchers focus on drug delivery vehicles with high transfection efficiency. 14,15 In the early years, viral vectors were the most widely used vehicles to deliver gene drugs. However, they may induce immune responses and mutagenesis in vivo. 16,17 Moreover, they can also cause various toxic and immune side effects which greatly limit their clinical applications. 18,19 In recent years, owing to their excellent biosafety and efficiency, the usage of non-viral vectors, including liposomes, 20,21 lipid nanoparticles 22,23 and extracellular vesicles (EVs), 24,25 has been an active line of research in gene therapy. EVs as non-viral vectors have been the subject at the forefront of gene delivery in recent years. 26,27 They can inherit the properties of parent cells and obtain some components of parent cells (eg, proteins, lipids, and nucleic acids). 28 Moreover, EVs present the advantages of good biocompatibility, low toxicity, 29 low immunogenicity, 30 and easy engineering modification. 31 Additionally, EVs can protect nuclear acids and other biologica -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology